Table 3.
Incidence rates (per 1,000 patients-day) of resistant bacteria
| Period 1 (2005) | Period 2 (2006–2008) | p value | |
|---|---|---|---|
|
Cohort patients | |||
| Bacteremia due to Cip-R organisms* |
3.02 |
6.77 |
0.03 |
| Cip-R enterobacteria |
0.38 |
2.12 |
0.06 |
| Cip-R Pseudomonas aeruginosa |
0.38 |
0.63 |
0.71 |
| ESBL production |
0.38 |
1.27 |
0.26 |
| Cip-R Staphylococcus aureus |
0 |
0.63 |
0.26 |
| Cip-R CONS |
2.27 |
2.75 |
0.72 |
|
Non-cohort patients in the hematology unit | |||
| Cip-R enterobacteria |
0.53 |
2.54 |
0.004 |
| Cip-R Pseudomonas aeruginosa |
0.70 |
0.32 |
0.39 |
| ESBL production |
0.52 |
1.59 |
0.08 |
| Cip-R Staphylococcus aureus |
0 |
0.16 |
0.52 |
| Cip-R CONS |
2.64 |
2.23 |
0.65 |
|
Hospital | |||
| Cip-R enterobacteria |
0.76 |
0.64 |
0.15 |
| Cip-R Pseudomonas aeruginosa |
0.22 |
0.21 |
0.78 |
| ESBL production |
0.56 |
0.53 |
0.74 |
| Cip-R Staphylococcus aureus |
0.33 |
0.23 |
0.06 |
| Cip-R CONS | 0.68 | 0.60 | 0.33 |
Cip-R = ciprofloxacin-resistant; ESBL = extended spectrum beta-lactamase; CONS = coagulase-negative staphylococci; *Total number of bacteremia due to quinolone-resistant organisms available in the cohort only.